Open AccessIvabradine and AF: Coincidence, Correlation or a New Treatment?
Author(s) -
Mahmoud Abdelnabi,
Ashraf Uddin Ahmed,
Abdallah Almaghraby,
Yehia Saleh,
Haitham Badran
Publication year - 2020
Publication title -
arrhythmia and electrophysiology review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.008
H-Index - 18
eISSN - 2050-3377
pISSN - 2050-3369
DOI - 10.15420/aer.2019.30.2
Subject(s) - ivabradine , cardiology , medicine , heart failure , sinus rhythm , heart rate , food and drug administration , clinical trial , angina , clinical practice , rhythm , atrial fibrillation , pharmacology , blood pressure , physical therapy , myocardial infarction
Ivabradine is a heart rate-lowering agent that inhibits pacemaker funny current (I f ). It has been approved by the European Medicines Agency and the US Food and Drug Administration for patients with stable angina and heart failure (HF). AF is a common issue especially in ischaemic heart disease and HF patients. In contrast to experimental findings and a limited number of clinical trials that demonstrate the emerging role of ivabradine for heart rate control in AF or maintenance of sinus rhythm, there is accumulating contradictory data indicating that there is, in fact, an increased incidence of new-onset AF among people who are taking ivabradine in clinical practice. This article reviews the most recent evidence highlighting the diversity of data in relation to the use of ivabradine and the onset of AF and whether it has a legitimate role in AF treatment and the maintenance of sinus rhythm.